Stimvia: AI-Powered Non-Invasive BCI | Czech Neurotech
- Stimvia, a Czech startup, is making waves with its URIS system, a non-invasive neuromodulation technology.
- The URIS system targets the brain via the peroneal nerve behind the knee.
- Pilot studies at Ostrava University hospital revealed that Parkinson's patients using URIS experienced reduced tremors and improved life quality.Professor David Skoloudik, vice-dean for research at Ostrava University's Medical...
Explore how Stimvia,a Czech neurotech startup,leverages AI too advance non-invasive brain-computer interfaces.Their URIS device, a primary_keyword using non-invasive neuromodulation, demonstrates promising results in treating neurological secondary_keyword such as Parkinson’s disease and multiple sclerosis. Clinical trials show improved motor function and quality of life, offering a potential alternative to traditional treatments. Stimvia is expanding across Europe and pursuing FDA approval, paving the way for broader accessibility of this innovative technology. Stay informed with News Directory 3 on the latest developments. Discover what’s next in the future of neurological intervention.
Stimvia’s URIS Device Shows Promise in Neurological Disorders
Stimvia, a Czech startup, is making waves with its URIS system, a non-invasive neuromodulation technology. founded by Lukáš Doskočil, a medical device executive, Stimvia’s device uses electrical pulses delivered through the leg to stimulate deep brain structures.Initially designed for overactive bladder treatment, URIS is now showing potential in managing Parkinson’s disease, multiple sclerosis, and Restless Leg Syndrome.
The URIS system targets the brain via the peroneal nerve behind the knee. doskočil explained that the proprietary electrodes send signals along nerve pathways to the prefrontal cortex, negating the need for surgery or implants. “We did a mechanistic study using functional MRI and showed stimulation effects in deep brain structures,” Doskočil said. “That’s never been done non-invasively before.”
Pilot studies at Ostrava University hospital revealed that Parkinson’s patients using URIS experienced reduced tremors and improved life quality.Professor David Skoloudik, vice-dean for research at Ostrava University’s Medical Faculty, noted significant improvements in motor symptoms and overall well-being without serious side effects. Another clinical paper suggests URIS may outperform traditional nerve stimulation for bladder dysfunction, avoiding needles and surgery.
The URIS device connects to a companion app, collecting session data, monitoring symptoms, and adapting stimulation. The latest version uses AI to optimize electrode placement and pulse parameters. Doskočil calls it a “virtual doctor” that personalizes treatment using real-time body feedback, marking a breakthrough in non-invasive therapy.
While larger U.S. companies dominate the neuromodulation field, Stimvia, with 15 employees and manufacturing in Pardubice, Czech Republic, has raised $8 million and is planning a Series A round.Having shipped over 200 units,the company is expanding across Europe,with Denmark as its first foreign market. Clinics in France, Italy, Spain, Greece, the Netherlands, and the UK are now adopting the device. Stimvia recently secured MDR certification from TÜV SÜD, paving the way for EU healthcare reimbursement and potential FDA approval in the U.S.
The implications extend beyond overactive bladder, a condition affecting an estimated 500 million to 1 billion people